Oncology
News
Overall Survival Advantage Eludes Afatinib in NSCLC
Major Finding: Median overall survival was 10.78 months with afatinib plus best supportive care vs.
News
Targeting Met Delays Progression in Advanced NSCLC
Major Finding: Median progression-free survival increased from 6.4 weeks with erlotinib and placebo to 12.4 weeks with the combination of...
News
In the Pipeline: Figitumumab Active in Refractory Ewing's Sarcoma
Major Finding: Median progression-free survival was 1.87 months and median overall survival was 8.87 months, with greater effect in those with a...
News
WHI: HT Raises Long-Term Breast Cancer Incidence, Disease Stage, and Mortality
Major Finding: Women who took combined estrogen/progestin therapy had a significantly higher rate of breast cancer (0.42% per year), a higher...
News
Cetuximab Trial Points Toward Targeting EGFR in Triple-Negative Breast Cancer
Major Finding: The overall response rate doubled from 10.3% with cisplatin alone to 20% with cetuximab plus cisplatin (P = .11).Data Source:...
News
FDA Panel Does Not Recommend Dosing Change for Aranesp
News
Basal Thyroglobulin Values Guide Intensity of Thyroid Cancer Follow-Up
Major Finding: In 425 patients who were treated for differentiated thyroid cancer, biochemical evidence of persistent disease (a stimulated...
News
Type 2 Diabetes Linked to Higher Risk for Colorectal Adenomas
News
Large Thyroid Nodules Linked to High Malignancy Risk
Major Finding: Thyroid nodule size is the main indication for surgical referral in patients with nondecisive fine-needle aspirations.Data Source:...